Wilmington – Attorney General Beau Biden announced today that his office has joined 41 other State Attorneys General in reaching a $35 million nationwide settlement with Pfizer Inc, as parent of Wyeth Pharmaceuticals Inc., over allegations the company unlawfully promoted Rapamune, an immunosuppressive drug currently approved by the FDA for use in preventing organ rejection after kidney transplant surgery. Delaware will receive $423,000, which will be paid to the Attorney General’s Consumer Protection Fund.
“We are acting to protect patients by ensuring that pharmaceutical companies market their drugs only for uses that are approved and safe,” Biden said.
The states allege that Wyeth violated state consumer protection laws by misrepresenting the uses and benefits of Rapamune, including making representations related to the unapproved (off-label) use of the drug following an organ transplant other than a kidney transplant, the unapproved protocol of converting patients to Rapamune after initially receiving a different drug, and using Rapamune in unapproved drug combinations.
In addition to its $35 million payment, under the terms of the settlement filed today for approval in Superior Court in New Castle County Pfizer is required to ensure that its marketing and promotional practices do not unlawfully promote Rapamune, or any Pfizer product. Specifically, Pfizer is prohibited from:
Today’s action follows a multi-state settlement this past June with GlaxoSmithKline that resolved allegations the company unlawfully promoted its asthma drug, Advair, and antidepressant drugs, Paxil and Wellbutrin by misrepresenting the uses and qualities of these drugs. Delaware received $1 million in that action.
# # #
Related Topics: consumer protection • Protecting Communities
Built by the Government Information Center